SNRIs and SSRIs are both classes of antidepressants
SSRIs currently have FDA labeled indications to treat the following conditions: Major depressive disorder Generalized anxiety disorder Bulimia nervosa Bipolar depression [2] Obsessive-compulsive disorder
MAXALT is contraindicated in patients with: • Ischemic
Rizatriptan benzoate tablets are contraindicated in patients with: • Ischemic coronary artery disease (angina pectoris, history of myocardial infarction, or documented silent ischemia), or other significant underlying cardiovascular disease [see Warnings and Precautions (5
Common Maxalt side effects may include: dizziness, drowsiness, tired feeling; or
are well-characterized
For example, antidepressants help treat obsessive-compulsive disorder, social phobia, panic disorder, generalized anxiety disorder (GAD), and post-traumatic stress disorder (PTSD)
Rizatriptan benzoate orally disintegrating tablets are contraindicated in patients with: when they were not
Rizatriptan (Maxalt) is available as a lower-cost generic tablet and an orally disintegrating tablet (ODT) that's placed on the tongue
(SSRIS) • fluoxetine tell your doctor if these contraindications apply to you
Age: Rizatriptan pharmacokinetics in healthy elderly non-migraineur volunteers (age 65-77 years) were similar to those in younger non-migraineur volunteers (age 18-45 years)
In a study of the interaction between the selective serotonin reuptake inhibitor (SSRI) paroxetine 20 mg/day for 2 weeks and a single dose of rizatriptan benzoate tablets 10 mg in healthy subjects (n = 12), neither the plasma concentrations of rizatriptan nor its safety profile were affected by paroxetine [see Warnings and Precautions (5
Doses should be separated by at least 2 hours, and no more than 30mg in any 24-hour period
Rizatriptan benzoate tablets are available for oral administration in strengths of 5 mg and 10 mg (corresponding to 7
They have a relatively wide therapeutic index, and although a number of minor pharmacokinetic interactions have been observed, few are likely to be clinically significant
Sedating antidepressants such as tricyclics, tetracylics (mirtazepine and mianserin) and agomelatine in combination with opioids can exacerbate drowsiness which can increase the risk of falls and respiratory depression